The General Hospital Corporation

Verinata Health, Inc.

Gpb Scientific, LLC

Fate Therapeutics, Inc.

Boss Logic, LLC

Rosetta Inpharmatics, Inc.

Ghc Technologies, Inc.

Merck Sharp + Dohme Corp.

Juno Therapeutics Gmbh

Knapp Investment Company Limited

Gpr Scientific, LLC

Daniel D Shoemaker

Mehmet Toner

Ravi Kapur

Roland B Stoughton

Ronald W Davis

Scott D Shoemaker

Lee Thomas O'Donnell

James P Broder

David Robbins

John D Mendlein

Caroline Desponts

Christopher D Armour

Stewart Scherer

Bahram Valamehr

Martin Fuchs

Barb Ariel Cohen

Stephen H Friend

Matthew N Ashby

Steven J Altschuler

Lani Fang Wu

Betsy Rezner

Eigen Peralta

Jonathan Rosen

Ian Hardy

Lucas James Thompson

Martin Hosking

Philip W Garrett-Engele

Christian Maine

Paul Grayson

Robert S Tacke

Philippe A Parone

Lisa Guerrettaz

Pratik Multani

Ronald W Davies

Compounds that either produce a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies, such as those providing improvements in one or more therapeutic outcomes, are provided.

Compositions and methods for immune cell modulation in adoptive immunotherapies

Compositions and methods for manufacturing induced immune regulatory cells comprising induced myeloid suppressive cells including MDSCs (myeloid-derived suppressor cells), dendritic cells, macrophages, and subpopulations thereof are provided. Also provided are methods and compositions for further modifying and modulating the induced immune regulatory cells to achieve enhanced therapeutic potential in treating autoimmune disorders, hematological malignancies, solid tumors, viral infections, neurodegenerative disorders, inflammatory conditions, or GvHD.

Composition and methods for inducing myeloid suppressive cells and use thereof

The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, e.g. aneuploidy. The present invention involves labeling regions of genomic DNA in each cell in said mixed sample with different labels wherein each label is specific to each cell and quantifying the labeled regions of genomic DNA from each cell in the mixed sample. More particularly the invention involves quantifying labeled DNA polymorphisms from each cell in the mixed sample.

Rare cell analysis using sample splitting and DNA tags

The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, i.e. aneuploidy. In addition, the present invention provides methods to determine when there are insufficient fetal cells for a determination and report a non-informative case. The present invention involves quantifying regions of genomic DNA from a mixed sample. More particularly the invention involves quantifying DNA polymorphisms from the mixed sample.

Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats

The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.

Enhanced stem cell composition

The invention provides cell potency assays for measuring, determining, identifying, confirming, or validating the therapeutic potential of a cell population. Cell potency assays may be performed with various types of cells, including stem or progenitor cells, such as, for example, hematopoietic stem or progenitor cells. Cell potency assays may also be performed on stem or progenitor cells that have been treated with one or more agents to enhance therapeutic potential. Hematopoietic cells having therapeutic potential are useful in downstream clinical applications for increasing engraftment, reconstitution, homing, and proliferation in vivo.

Cell potency assay for therapeutic potential

A social media computer system includes a database that is in network communication with a first mobile phone and a second mobile phone. The database receives a first set of data from the first mobile phone and a second set of data from the second mobile phone. The database allows the second mobile phone to access the first set of data only after the second mobile phone authorizes the first mobile phone via the database to access the second set of data. A portion of the first set of data accessed by the second mobile phone can be automatically or manually synchronized to the memory of the second mobile phone. A user of the second mobile phone can control the portion of the first set of data synchronized to the second mobile phone. The first set of data can include video, audio, geographic location, visual and textual data. The first mobile phone has a memory, and a portion of the second set of data can be synchronized to the memory of the first mobile phone.

System and method for secure reciprocal exchange of data

A social media computer system and method for transmission of data between a first mobile phone and a second mobile phone includes a database that is configured to be in network communication with the first mobile phone and the second mobile phone. The database is configured to receive a first set of data input by the first mobile phone and a second set of data input by the second mobile phone. The database is configured to allow the second mobile phone to access at least a portion of the first set of data only after the second mobile phone authorizes the first mobile phone via the database to access the second set of data. The database can include a plurality of privacy levels that are alternately selectable by the first mobile phone to control the amount of the first set of data that is accessible by the second mobile phone. The first set of data can include one or more of video data, audio data, geographic location information, visual data and textual data, input into the database via the first mobile phone.

A system for transmission of data between a first device operated by a first user and a second device operated by a second user includes a database that is in network communication with the first device and the second device. The database receives a first set of data input by the first user and a second set of data input by the second user. The database allows the second user to access a first portion of the first set of data only after the second user authorizes the first user via the database to access a first portion of the second set of data. Additionally, the database can allow the second user to have access to the first portion of the first set of data from the database only after the first user authorizes the second user via the database to access the first portion of the first set of data from the database. At least one of the first portion of the first set of data and the first portion of the second set of data includes video data, audio data, geographic location information, visual data and/or textual data. At least one of the first device and the second device can be a mobile phone.

Growing community of inventors

Bothell, WA, United States of America

Daniel D Shoemaker